Researchers from Fudan University have discovered that a gut-restricted compound may offer a new approach to treating Polycystic Ovary Syndrome (PCOS).
The study, published in Reproductive and Developmental Medicine, suggests that activating a specific receptor in the intestines could correct both the metabolic and reproductive symptoms of the disorder.
Key Findings
- Researchers from Fudan University tested fexaramine (Fex), a compound that activates intestinal FXR and remains localized in the gut, in two mouse models of PCOS.
- Fex treatment improved metabolic markers: It reduced weight gain, improved glucose tolerance, and increased insulin sensitivity.
- Fex restored disrupted reproductive cycles, reduced abnormal ovarian follicles, increased corpus luteum formation, lowered circulating testosterone and androstenedione levels, and normalized luteinizing hormone and anti-Müllerian hormone levels.
- Transcriptomic analysis showed Fex altered gene pathways related to follicular development, steroid hormone production, inflammation, and glucose and lipid metabolism.
Background
PCOS is a common hormonal disorder in women of reproductive age, associated with irregular periods, infertility, weight gain, insulin resistance, and elevated male hormone levels. Current treatments manage symptoms but do not address underlying causes. Previous studies have linked PCOS to gut bacteria and bile acid signaling. FXR is a receptor activated by bile acids that regulates metabolism and hormones, but systemic FXR activation has shown mixed results and safety concerns.
Significance
The study suggests that intestinal FXR signaling may serve as a communication hub between the gut and reproductive system, supporting the concept of a "gut–ovary axis" in PCOS. Fexaramine, which is not processed by the liver, may avoid the risks of systemic drugs.
Limitations and Next Steps
The authors note that further research is needed to understand mechanisms by which intestinal FXR activation improves ovarian function. Mouse models do not fully replicate human PCOS, and clinical studies are required before conclusions about human application can be drawn.
Publication
The study was published in Reproductive and Developmental Medicine.